---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-055056"
form_type: "8-K"
ticker: "LNSR"
cik: "0001320350"
company_name: "LENSAR, Inc."
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:19:24.541941+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LENSAR Q3 2021 revenue $8.3M (+16% YoY), net loss widens to $6.2M

## Summary
- Revenue $8.3M, up 16% YoY; procedure volumes grew 23% over Q3 2020.
- Net loss of $6.2M ($0.65 loss per share) vs. $4.8M loss ($0.64 per share) in Q3 2020.
- R&D spending surged 59% to $3.2M, driven by development of ALLY Adaptive Cataract Treatment System.
- Cash and equivalents $32.3M; cash utilization $2.2M in the quarter.
- Adjusted EBITDA was ($3.9M) compared to ($0.4M) in Q3 2020, reflecting higher R&D and SG&A.

## SEC filing metadata
- accession: 0001564590-21-055056
- form_type: 8-K
- ticker: LNSR
- cik: 0001320350
- company_name: LENSAR, Inc.
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1320350/000156459021055056/0001564590-21-055056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1320350/000156459021055056/lnsr-8k_20211108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-055056
- JSON: https://secwatch.observer/filing/0001564590-21-055056.json
- Plain text: https://secwatch.observer/filing/0001564590-21-055056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.